Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Investing Activities (2016 - 2021)

Historic Cash from Investing Activities for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $23.7 million.

  • Neurocrine Biosciences' Cash from Investing Activities rose 11604.6% to $23.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$130.2 million, marking a year-over-year decrease of 327560.98%. This contributed to the annual value of -$126.8 million for FY2024, which is 7285.38% up from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Cash from Investing Activities is $23.7 million, which was up 11604.6% from -$126.2 million recorded in Q3 2021.
  • In the past 5 years, Neurocrine Biosciences' Cash from Investing Activities ranged from a high of $93.4 million in Q2 2020 and a low of -$213.3 million during Q2 2017
  • For the 5-year period, Neurocrine Biosciences' Cash from Investing Activities averaged around -$41.6 million, with its median value being -$40.2 million (2017).
  • As far as peak fluctuations go, Neurocrine Biosciences' Cash from Investing Activities plummeted by 126250.0% in 2017, and later soared by 3123333.33% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Cash from Investing Activities (Quarter) stood at -$59.4 million in 2017, then plummeted by 78.87% to -$106.2 million in 2018, then crashed by 56.44% to -$166.2 million in 2019, then increased by 11.13% to -$147.7 million in 2020, then surged by 116.05% to $23.7 million in 2021.
  • Its last three reported values are $23.7 million in Q4 2021, -$126.2 million for Q3 2021, and -$90.8 million during Q2 2021.